Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. The company's President and CEO, Panna Sharma, along with members of the management team, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR® and Open-Medicine AI platforms. A webcast replay will be available through the investor relations section of Lantern Pharma's website following the event.
This announcement is significant for investors and the oncology industry as it underscores Lantern Pharma's continued integration of artificial intelligence into drug development. The company's proprietary RADR® platform is designed to transform the development of cancer therapies by using AI and machine learning to analyze vast datasets, potentially accelerating the identification of promising drug candidates. The upcoming webcast will offer stakeholders a chance to gauge the company's progress and future direction.
Lantern Pharma's clinical pipeline includes several promising candidates. LP-184 is an acylfulvene being developed for multiple cancers, including pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. LP-284, a TC-NER targeting compound, is being studied in hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is currently being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. These trials highlight the company's focus on addressing significant unmet medical needs.
A key development for Lantern Pharma is the commercial availability of withZeta.ai, its multi-agentic AI co-scientist platform. Now offered as a subscription-based research platform for the global biomedical and drug development community, withZeta.ai represents a new revenue stream for the company. This move signals Lantern Pharma's ambition to not only use AI internally but also to offer its technology to other researchers, potentially reshaping how cancer drug discovery is conducted worldwide.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. This global footprint positions Lantern Pharma to attract top talent and collaborate with international partners. For investors, the webcast will provide insights into how these initiatives are translating into financial performance and strategic growth.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. The full press release can be viewed at https://ibn.fm/l80kv.
